Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LRIG2 divergent transcript (LRIG2-DT) is a long non-coding RNA transcribed from the bidirectional promoter shared with the LRIG2 gene[5][3]. Its expression is modulated by the presence or absence of a nearby SVA retrotransposon insertion polymorphism (RIP), which also affects local methylation and expression of the coding gene LRIG2[2][3][5]. There is no demonstrated therapeutic targeting or receptor function for LRIG2-DT, and its direct biological roles remain largely undefined. It is primarily of interest in genomic studies focusing on transcriptional regulation and epigenetics—especially regarding how mobile genetic elements like SVAs influence gene expression in the human brain and other tissues[2][3][5]. As of the latest data, LRIG2-DT is classified as a lncRNA with uncertain or context-specific biological significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LRIG2 divergent transcript (LRIG2-DT).